Experimental pill breakthrough sees cancer vanish in a third of leukaemia patients

    WORLD  26 March 2023 - 00:03

    Terminal leukaemia patients who were not responding to treatment now have hope for a cure, thanks to a new experimental pill called revumenib.

    This drug has completely eliminated cancer in a third of the participants in a long-awaited clinical trial in the United States.

    Although not all patients showed complete remission, scientists remain hopeful as the results indicate that the pill might pave the way to a cure for leukaemia in the future.

    "We're incredibly hopeful by these results of patients that received this drug. This was their last chance," said study co-author Dr Ghayas Issa, a leukaemia physician at the MD Anderson Cancer Center at the University of Texas.

    "They have progressed on multiple lines of therapy and a fraction of them, about half, had disappearance of their leukaemia cells from their bone marrow," he told Euronews Next.

    How does this pill work?

    Acute myeloid leukaemia (AML) is a type of cancer that attacks the bone marrow, where blood cells are produced, and causes the uncontrolled production of defective cells.

    Revumenib is a new class of targeted therapy for acute leukaemia that inhibits a specific protein called menin. The drug works by reprogramming leukaemia cells back into normal cells.

    Menin is involved in the complex machinery that gets hijacked by leukaemia cells and causes normal blood cells to turn into cancerous ones.

    By using revumenib, Issa explained, the engine is turned off and leukaemia cells are turned back into normal cells, resulting in remission.

    This formula has already saved 18 lives as part of the clinical trial, whose promising results were published this month in Nature.

    The preliminary results showed that 53 per cent of patients responded to revumenib, and 30 per cent had a complete remission with no cancer detectable in their blood.

    Based on the data from this trial, in December 2022 the US Food and Drug Administration granted revumenib "breakthrough therapy designation" to help fast-track its development and regulatory review.

    A leukaemia cure, but not for everyone

    "This is definitely a breakthrough and it's a result of years of science. A lot of groups had worked hard in the lab to understand what is causing these leukaemias," Issa said.

    However, he explained that the drug does not work for all patients. It is for a specific subset of leukaemias that generally have missing or mislabeled genes or a chromosome fusion.

    The experimental pill targets the most common mutation in acute myeloid leukaemia, a gene called NPM1, and a less common fusion called KMT2A. Combined, these mutations are estimated to occur in about 30 to 40 per cent of people with acute myeloid leukaemia.

    The phase 1 trial enrolled 68 patients at nine US hospitals. All of them had seen their leukaemia return after other treatments or had never responded well to traditional chemotherapy drugs in the first place.

    Among them was Algimante Daugeliate, a 23-year-old Lithuanian architect diagnosed with leukaemia. She had received two bone marrow transplants from her sister, but all other treatments had failed. Her doctors had even considered palliative care to ease her suffering.

    "I was desperate. It was like living through a horrible movie. I felt like death was imminent, and I was just 21 years old," she told El Pais.

    However, once she started taking revumenib two years ago, Daugeliate made a full recovery. Since then, she has been able to resume her normal life, graduating from college and working at an architecture studio in Copenhagen.

    Strong impact for limited side effects

    According to Issa, although this drug is fairly safe when compared to standard treatments for leukaemia, two main side effects have been identified.

    The first affects the heart’s electrical system and can be detected with an electrocardiogram (ECG). However, reducing the dosage or halting the treatment resolved the issue in all cases, Issa said.

    The second side effect is referred to as differentiation syndrome - a group of potentially life-threatening reactions to blood cancer treatments - but it can be managed effectively if it’s recognised early and appropriate measures are taken to shut it down. According to Issa, all cases of differentiation syndrome in this study were successfully managed without any complications for the patients.

    The study is still in its early stages and the results remain preliminary. Phase I studies like this one aim to test whether a drug is safe and to find the highest dose that can be given to them without causing severe side effects.

    A phase II study specifically looking at the effectiveness of revumenib is now underway.

    Twelve patients in the trial who responded to the drug went on to receive a stem cell or bone marrow transplant. Such transplants require that patients have no cancer or only very low levels of cancer in their blood - and revumenib helped them get there.

    While the experimental pill is not a definitive cure, the researchers who worked on the trial are optimistic.

    "In the future, we plan to combine this pill with standard treatments that we have currently for acute leukaemias," said Issa.

    "That is the most likely strategy to get us to cures where patients don't have to see leukaemia doctors after that and don't need treatments for leukaemia".


    Subscribe to our Telegram channel

Read also

Iran not to surrender to West's bullying, sanctions

24 April 2024 - 18:45

Germany's position on Taurus remains unchanged

24 April 2024 - 20:59

Sweden’s plan for worst-case scenario War spreading in Europe

24 April 2024 - 20:40

German business activity increasing in April

24 April 2024 - 20:48

Mark Rutte seeks Türkiye's backing for new job A new pair of hands

24 April 2024 - 16:55

France proposes new EU sanctions to fight Russian disinformation

24 April 2024 - 20:18
Latest news

    EU’s 2050 net zero goals at risk as electric vehicle rollout faces setbacks

    25 April 2024 - 07:03

    World’s largest wealth fund issues inflation warning on hot commodity markets

    real wildcard

    25 April 2024 - 05:04

    How US F-16 fighter jets stack up to Su-35s sent to Iran?

    25 April 2024 - 03:05

    Belgian brewer whose body produces its own alcohol cleared of drink driving

    25 April 2024 - 01:03

    Milan becomes latest European hotspot to battle overtourism

    No ice cream and pizza after midnight

    24 April 2024 - 23:00

    Germany's position on Taurus remains unchanged

    24 April 2024 - 20:59

    German business activity increasing in April

    24 April 2024 - 20:48

    Baku to host space technology conf for Central Asian region

    24 April 2024 - 20:45

    Sweden’s plan for worst-case scenario

    War spreading in Europe

    24 April 2024 - 20:40

    President’s special rep: Karabakh can be called eco-region of Azerbaijan

    24 April 2024 - 20:32

    Azerbaijani energy minister holds talks with Algerian delegation on advancing bilateral cooperation

    24 April 2024 - 20:28

    China's Xiaomi selling more EVs than expected

    raising hopes it can break even sooner

    24 April 2024 - 20:24

    France proposes new EU sanctions to fight Russian disinformation

    24 April 2024 - 20:18

    European Commission disburses additional $1.6 billion in bridge financing to Ukraine

    24 April 2024 - 20:16

    Serb Member of Presidency of Bosnia & Herzegovina Željka Cvijanović invited to COP29

    24 April 2024 - 20:12

    UK to transfer Paveway IV bombs to Ukraine


    24 April 2024 - 19:59

    Azerbaijani minister, Uzbek ambassador discuss defence cooperation issues


    24 April 2024 - 19:48

    State reception commences to honor Kyrgyz President Sadyr Zhaparov

    24 April 2024 - 19:40

    MFA: Azerbaijan continues contributing to peace, security

    24 April 2024 - 19:35

    Kyrgyz president pays tribute to Azerbaijani martyrs

    24 April 2024 - 19:30

    Azerbaijani MPs, assistants to US congressmen discuss relations with Armenia, Russia


    24 April 2024 - 19:27

    Kyrgyz president pays respect to Great Leader Heydar Aliyev

    24 April 2024 - 19:19

    Turkish president appeals to Armenian Patriarch

    24 April 2024 - 19:15

    Türkiye rejects “one-sided” statements on 1915 events

    24 April 2024 - 19:09

    Air France plane safely evacuated at Heydar Aliyev Int’l Airport

    24 April 2024 - 19:08

    United Kingdom Maritime Trade Operations receives report of incident near Djibouti

    24 April 2024 - 19:03

    Azerbaijani, Kyrgyz leaders unveil monument to prominent novelist

    24 April 2024 - 18:55

    US Central Command, Royal Jordanian Air Force conduct humanitarian airdrops into Gaza

    24 April 2024 - 18:51

    Iran not to surrender to West's bullying, sanctions

    24 April 2024 - 18:45

    ADA University rep: Kyrgyzstan to become third country participating in school construction in Karabakh

    24 April 2024 - 18:36

    China’s president visits Belgrade around anniversary of NATO embassy bombing

    24 April 2024 - 18:22

    Best way to avoid war is to “talk less, prepare more”

    Finland’s president says

    24 April 2024 - 18:07

    International experts view restoration activities in Lachin

    24 April 2024 - 18:03

    Jamaica recognizes State of Palestine

    24 April 2024 - 17:53

    "Peoples of South Caucasus should resolve their differences independently"

    Foreign analysts on Caliber.Az

    24 April 2024 - 17:40

    HAMAS holding hostage 30 high-ranking Israeli security forces members

    24 April 2024 - 17:38

    Top 100 fastest-growing FDI destinations

    Baku ranks 3rd

    24 April 2024 - 17:30

    Argentina asks Interpol to arrest Iranian minister over attack

    24 April 2024 - 17:23

    Russia urges Armenia to clarify National Assembly president’s speech

    Following scandalous statements

    24 April 2024 - 17:19

    Three signs US could be heading for recession

    Expert analysis

    24 April 2024 - 17:08

All news